Testing a new gene therapy injection for wet age-related macular degeneration

Plain-English translation of NCT07776522 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether , a new gene therapy treatment given as a single injection directly under the retina, can safely help people with wet age-related macular degeneration (a serious eye condition that causes vision loss). The trial will compare two different doses of this new treatment against aflibercept, a standard anti-VEGF medication that people with this condition already receive regularly.

Current treatments for wet macular degeneration require repeated injections over many months or years, which can be burdensome for patients. This trial is exploring whether a single gene therapy injection could provide longer-lasting benefit, potentially reducing the need for frequent repeat treatments.

Do you qualify?

You likely qualify if…

you are between 50 and 85 years old
you have been diagnosed with wet age-related macular degeneration that requires treatment
your eye has previously responded well to aflibercept (a standard treatment for this condition)
you have had cataract surgery (so you have an artificial lens) in the study eye
your vision in the study eye falls within a certain range (19–78 ETDRS letters)
you are able to give informed consent and follow the study protocol

You likely don't qualify if…

you have other eye conditions besides wet macular degeneration that could affect the results
you have had eye surgery or eye steroid injections within the past 4 weeks
you have an active eye infection, inflammation, or a history of uveitis
you are blind in one eye or have vision loss below 19 ETDRS letters in your non-study eye
you have serious systemic illness, active cancer, or have participated in another clinical trial recently

What participation looks like

If you enroll, you will be randomly assigned to receive either a single subretinal injection of the new gene therapy (at one of two dose levels) or repeated aflibercept injections over about a year. The trial will track your vision and eye health over time with regular visits and eye exams to see how well the treatment works and whether it is safe. The study involves about 50 participants at West China Hospital.

AI-generated summary from trial data · Aug 22, 2026 · Not medical advice

Trial locations(16 sites)

China

Beijing Hospital, Beijing, Beijing Municipality

Peking University People's Hospital, Beijing, Beijing Municipality

The Second Hospital of Jilin University, Jilin City, Changchun

Southwest Hospital, Army Medical University（Southwest Hospital）, Chongqing, Chongqing Municipality

Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, Guangdong